Tuesday , January 16 2018
Home / Precision Medicine

Precision Medicine

FDA Approves AstraZeneca’s PARP Inhibitor to Treat Breast Cancer Patients with a BRCA Gene Mutation

The U.S. Food and Drug Administration today expanded the approved use of Lynparza (olaparib tablets) to include the treatment of patients with certain types of breast cancer that have spread (metastasized) and whose tumors have a specific inherited (germline) genetic mutation, making it the first drug in its class (PARP …

Read More »

OPKO’s GeneDx and Radboud Collaborate to Identify Novel Genes and Pathways to Understand Genetic Diseases

MIAMI, Jan. 12, 2018 (GLOBE NEWSWIRE) — OPKO Health, Inc. (NASDAQ:OPK), announces today that GeneDx, Inc., a subsidiary of OPKO’s BioReference Laboratories, has entered into a research collaboration with the Radboud University Medical Center, Nijmegen, Netherlands. Through the agreement, GeneDX and Radboud aim to identify novel genes and pathways to help understand the …

Read More »

Incorporation of Thermo Fisher QuantStudio 5 PCR Instrument into Target Selector Platform Improves Detection of Lung Cancer Biomarkers

SAN DIEGO, Jan. 9, 2018 /PRNewswire/ — Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces that incorporation of the Thermo Fisher QuantStudio5 (QS5) real-time PCR instrument into the …

Read More »

GeneCentric Therapeutics Announces Research Collaboration on Drug Response to Biomarkers for Lung Cancer

DURHAM, N.C.–(BUSINESS WIRE)–GeneCentric Therapeutics, Inc. today announced a research collaboration to evaluate the potential of GeneCentric’s Cancer Subtype Platform (CSP®) to identify responders to G1 Therapeutics’ oral CDK4/6 inhibitor G1T38 for the treatment of non-small cell lung cancer (NSCLC). As part of the research collaboration, GeneCentric will apply its lung …

Read More »

Innovation Pharmaceuticals Obtains Evidence of Molecular Pathways Modulation in Tumors from Patients in Kevetrin Mid-Stage Ovarian Cancer Trial

BEVERLY, Mass., Dec. 27, 2017 (GLOBE NEWSWIRE) — Innovation Pharmaceuticals Inc., (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to announce highly encouraging preliminary data from the first patients treated in the Company’s Phase 2a clinical trial (see NCT03042702) of Kevetrin for ovarian cancer. Modulation of the p53 …

Read More »

Statement from FDA Commissioner Gottlieb on New FDA Efforts to Support More Efficient Development of Targeted Therapies

SILVER SPRING, Md., Dec. 15, 2017 /PRNewswire-USNewswire/ — In recent years, the medical community has experienced a shift in the way health care is practiced. Rather than focusing solely on how to treat an overall disease type, medical innovators are now exploring how to tailor treatments that target unique characteristics …

Read More »

Foundation Medicine to Present New Data Supporting FoundationOne®Heme to Advance Personalized Medicine in Blood Cancers

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Foundation Medicine, Inc. (NASDAQ:FMI) today announced that new data generated with FoundationOne®Heme, its comprehensive genomic profiling (CGP) assay for hematologic malignancies and sarcomas, will be presented at the American Society of Hematology (ASH) Annual Meeting. Data from a broad range of blood cancers, including acute myeloid leukemia (AML), myeloproliferative …

Read More »

Researchers Identify Potential Therapeutic Target in Aggressive Breast Cancer Cells

ORCHARD PARK, N.Y., Nov. 15, 2017 /PRNewswire/ — An especially aggressive breast cancer cell can respond to hormone therapy if they express a specific protein known as estrogen receptor beta (ERβ), according to new research published on the cover of Oncotarget. The findings also revealed additional molecules that the researchers …

Read More »

Blueprint’s BLU-285 Shows Strengthened Clinical Activity across Spectrum of KIT and PDGFRα Genotypes in Early-Stage GIST Study

CAMBRIDGE, Mass., Nov. 10, 2017 /PRNewswire/ — Blueprint Medicines Corporation (NASDAQ: BPMC), a leader in discovering and developing targeted kinase medicines for patients with genomically defined diseases, today announced new Phase 1 clinical data for BLU-285, a potent and highly selective KIT and PDGFRα inhibitor in development as a potential …

Read More »

Opdivo and Yervoy Combo Increased Overall Survival Across PD-L1 Expression Levels in Advanced RCC

PRINCETON, N.J.–(BUSINESS WIRE)–Bristol-Myers Squibb Company (NYSE:BMY) announced today results from a new exploratory analysis of the phase 3 CheckMate -214 trial evaluating Opdivo (nivolumab) plus Yervoy (ipilimumab) versus the standard of care, sunitinib, in intermediate- and poor-risk patients with previously untreated advanced or metastatic renal cell carcinoma (RCC). In an exploratory analysis of PD-L1 expression …

Read More »